Doxylamine

Introduction Overview

Generic Name

doxylamine

Brand Name

Unisom

Dosage Form

Oral tablet (sleep aid and allergy symptom relief)

Drug Class

Miscellaneous anxiolytics, sedatives and hypnotics

Pharmacokinetics

Absorption:
Doxylamine is well absorbed via the gastrointestinal tract following oral administration. Peak plasma concentrations are typically achieved within 2 to 3 hours post-dose. The absorption rate can be influenced by concurrent food intake; taking doxylamine with food or milk may reduce gastrointestinal discomfort but does not significantly affect bioavailability. The rapid absorption contributes to the quick onset of its sedative and antihistaminic effects, typically within 30 minutes to 1 hour.

Distribution:
Doxylamine extensively distributes throughout body tissues, demonstrating a high volume of distribution indicative of significant tissue binding, including central nervous system (CNS) penetration due to its lipophilic nature. Plasma protein binding is moderate to high, primarily to albumin, which can influence its interaction with other protein-bound drugs. The drug crosses the blood-brain barrier readily, accounting for its central sedative effects. Additionally, doxylamine can pass into breast milk, posing considerations for nursing mothers.

Metabolism:
The metabolism of doxylamine occurs mainly in the liver through hepatic microsomal enzymes. It undergoes extensive biotransformation primarily via demethylation and hydroxylation pathways. The cytochrome P450 system, especially CYP2D6, is believed to play a role in its metabolism, although interactions with this system are less pronounced compared to other drugs. The metabolites formed are generally inactive and undergo further conjugation before elimination.

Elimination:
Doxylamine and its metabolites are primarily excreted via the kidneys, with the majority eliminated in the urine as conjugated metabolites. The elimination half-life ranges approximately from 10 to 12 hours, supporting once-daily dosing for sleep aid indications. Factors such as renal function impairment can significantly alter the elimination kinetics, necessitating cautious use in affected patients. The relatively prolonged elimination half-life underpins the risk of residual daytime sedation if dosed too closely to waking hours or in elderly populations where clearance may be reduced.

Dosage Forms

Available Dosage Forms:
Unisom is marketed predominantly in oral tablet formulations intended for use as a sleep aid and relief of allergy and cold symptoms. The common over-the-counter form is the Unisom SleepTabs containing doxylamine succinate. Specific dosage strengths typically include 25 mg tablets.

Dosages for Adults and Adolescents:
For the treatment of insomnia, the recommended adult dose of doxylamine via Unisom is 25 mg taken approximately 30 minutes before bedtime. Dosing should not exceed once per 24 hours. For relief of allergy or cold symptoms, dosing may vary but generally aligns with similar dosing regimens, tailored to symptom control and limited for short-term use. The tablet should not be administered to children under 12 years without medical advice.

Specific Patient Populations:
Elderly patients are more sensitive to the sedative and anticholinergic effects of doxylamine and may require dose adjustments or avoidance due to increased risk of confusion, dizziness, and falls. Patients with glaucoma, benign prostatic hyperplasia, asthma, bronchitis, emphysema, or other chronic lung diseases should use doxylamine cautiously due to potential exacerbation of underlying conditions. Pregnant or breastfeeding women should avoid use unless specifically advised by a healthcare provider, considering possible adverse effects on the fetus or infant.

Mechanism Of Action

Doxylamine is a first-generation antihistamine that primarily exerts its effects by antagonizing the H1 histamine receptors centrally and peripherally. By blocking H1 receptors, it inhibits the action of endogenous histamine, a key mediator of allergic symptoms like itching, sneezing, and rhinorrhea. This receptor blockade mitigates histamine-mediated responses in the nasal mucosa and other body sites, alleviating allergic and cold symptoms.

In the central nervous system, doxylamine’s antagonism at H1 receptors accounts for its sedative properties. Crossing the blood-brain barrier, doxylamine depresses central neuronal activity, leading to drowsiness, making it effective as a short-term hypnotic agent for insomnia. This sedative effect is associated with its inhibition of wake-promoting histaminergic neurons in the tuberomammillary nucleus of the hypothalamus.

Additionally, doxylamine has anticholinergic properties through antagonism of muscarinic cholinergic receptors, contributing to side effects such as dry mouth, blurred vision, constipation, and urinary retention. This anticholinergic action also compounds its sedative effects but requires caution in populations susceptible to these adverse outcomes, like elderly patients or those with prostatic hypertrophy.

Compared to second-generation antihistamines, doxylamine’s ability to cause sedation reflects its greater CNS penetration. Clinically, this dual property as both an antihistamine and sedative enables doxylamine to relieve allergy symptoms while aiding sleep, distinguishing it from nonsedating antihistamines. Research supports its efficacy and safety in short-term use, although tolerance to sedative effects can develop with prolonged administration.

Pharmacological Actions

H1 histamine receptor antagonist with antihistaminic activity to alleviate allergy symptoms.
Central nervous system depressant through H1 receptor blockade, producing sedative and hypnotic effects.
Exhibits anticholinergic effects by muscarinic receptor antagonism, contributing to drying of secretions and potential side effects.
Blocks histamine-induced vasodilation and increased vascular permeability, reducing tissue edema and inflammation in allergic responses.
Reduces sneezing, rhinorrhea, and nasal congestion associated with allergic rhinitis and common colds.
Induces drowsiness by inhibiting central histaminergic neurotransmission involved in wakefulness.
Short-term hypnotic agent for the management of insomnia by promoting sleep onset.
Inhibits histamine-mediated itchiness and hives through peripheral receptor blockade.
May impair sweating through anticholinergic action, increasing risk of overheating.
Weakly depresses respiratory drive in susceptible individuals, necessitating caution with concurrent depressant drugs.
Possesses moderate oral bioavailability with effects observable within 30–60 minutes of administration.
Minimal potential for dependence or abuse compared to benzodiazepines or other hypnotics.
Metabolized by hepatic enzymes with inactive metabolites excreted renally.
Crosses the placenta and BBB, influencing considerations for use in pregnancy and lactation.
Can cause residual daytime sedation and impaired psychomotor performance in sensitive individuals.

Therapeutic Or Clinical Uses

Short-term treatment of insomnia to aid sleep initiation in adults.
Relief of symptoms associated with allergic conditions such as allergic rhinitis, including sneezing, itchiness, and watery eyes.
Management of cold-related symptoms, such as runny nose and nasal congestion.
Treatment of urticaria (hives) and skin rashes related to histamine release.
Symptomatic control of pruritus due to allergic dermatitis.
Used as a sleep aid in over-the-counter formulations for transient sleep disturbances.
Adjunctive therapy in multi-symptom cold and allergy medications containing antihistamines.
Clinical use in controlling nighttime allergy symptoms to improve sleep quality.
Reduction of nasal secretions in upper respiratory tract infections.
Management of mild anxiety and nervousness associated with insomnia in some clinical contexts.
Implementation in pediatric patients under strict medical guidance for allergy relief (age restrictions apply).
May be used off-label for motion sickness through its antihistaminic action.
Treatment consideration in elderly populations requires caution but can aid sleep disturbances with close monitoring.
Alternative sedative in patients intolerant of benzodiazepines or other hypnotics.
Non-prescription option for patients seeking relief from occasional insomnia or allergy symptoms.

Side Or Adverse Effects

Drowsiness and sedation, which may persist into the daytime.
Dry mouth, throat, and nose due to anticholinergic effects.
Constipation from decreased gastrointestinal motility.
Blurred vision caused by anticholinergic inhibition of accommodation.
Confusion, especially in elderly patients, potentially leading to delirium.
Dizziness and impaired coordination increasing risk of falls.
Urinary retention due to relaxation of bladder detrusor muscle.
Potential for paradoxical excitation in rare cases, presenting as nervousness or agitation.
Thickened bronchial secretions, which may exacerbate respiratory conditions.
Allergic reactions such as rash, urticaria, or, rarely, anaphylaxis.
Increased risk of heat stroke related to impaired sweating.
Gastrointestinal upset like nausea, though less common.
Headache attributable to central nervous system effects.
Tolerance development with prolonged use, reducing sedative efficacy.
Potential for interaction-related adverse effects when combined with CNS depressants.

Precautions

Use caution in elderly patients due to increased sensitivity to anticholinergic and sedative effects.
Avoid use in patients with narrow-angle glaucoma as anticholinergic activity can increase intraocular pressure.
Use cautiously in individuals with enlarged prostate or urinary retention history.
Patients with asthma, chronic bronchitis, emphysema, or other chronic pulmonary conditions should consult a healthcare provider prior to use.
Pregnant women should avoid use unless specifically directed by a physician due to limited safety data.
Breastfeeding mothers should not use without medical advice as doxylamine passes into breast milk and may suppress lactation.
Avoid concurrent use with other CNS depressants, including alcohol and sedative-hypnotics, to prevent excessive sedation or respiratory depression.
Patients should refrain from driving or hazardous activities until effects are known due to potential for impaired alertness and vision.
Do not exceed recommended dosage to minimize risk of toxicity and adverse reactions.
Should not be given to children under 12 years for insomnia, and use in younger children requires medical supervision.
May interfere with allergy skin testing; inform healthcare providers of drug use prior to testing.
Avoid use in individuals with hypersensitivity to doxylamine or related compounds.
Hydration and precaution during exercise, especially in hot weather, are important to prevent overheating.
Dose adjustment or avoidance is recommended in patients with hepatic or renal impairment.
Regular evaluation is needed if used for prolonged periods to assess for effectiveness and emergence of side effects.

Warnings

Risk of severe allergic reactions (anaphylaxis) requiring immediate medical attention.
Potential for confusion, hallucinations, and severe dizziness especially in overdose or sensitive populations.
Risk of profound sedation and respiratory depression when combined with other sedatives or narcotics.
Use is contraindicated in individuals allergic to doxylamine or formulation components.
Unisom may cause blurred vision impairing driving or operating machinery.
Excessive dosage can lead to anticholinergic toxicity manifested by dry mouth, urinary retention, tachycardia, and hyperthermia.
Use with caution in patients with a history of seizures as CNS depression may lower seizure threshold.
Not recommended for prolonged use due to risk of tolerance and rebound insomnia.
Possible risk of overdose in young children; keep out of reach and never share medications.
May worsen symptoms in patients with chronic respiratory diseases due to drying of secretions.
Potential to mask underlying conditions by relieving symptoms superficially without treating cause.
Discontinuation should be considered if cognitive impairment or significant adverse effects occur.
Avoid use during pregnancy and lactation unless benefits outweigh risks and under physician guidance.
Patients should disclose use prior to allergy skin testing or diagnostic procedures.
Cross-reactivity with other first-generation antihistamines may precipitate allergies.

Contraindication

Known hypersensitivity or allergy to doxylamine or any component of the formulation.
Patients with narrow-angle glaucoma due to risk of increased intraocular pressure.
Use during labor and delivery is contraindicated due to potential adverse effects on the fetus or neonate.
Should not be administered to children under 12 years for insomnia or without medical supervision.
Concurrent use with monoamine oxidase inhibitors (MAOIs) may exacerbate anticholinergic effects and is contraindicated.
Patients with severe urinary retention or obstructive uropathy should avoid use.
Individuals with severe hepatic impairment without specialist supervision.
Known volatile substance misuse history or patients predisposed to CNS depressant abuse.

Drug Interactions

Concurrent use with other CNS depressants (benzodiazepines, opioids, muscle relaxants) may increase sedation and respiratory depression risk.
Alcohol consumption potentiates central nervous system depressant effects of doxylamine.
Anticholinergic drugs may have additive side effects, increasing risk of dry mouth, urinary retention, and constipation.
Caution when used alongside other antihistamines to avoid excessive anticholinergic burden and toxicity.
Co-administration with monoamine oxidase inhibitors (MAOIs) can prolong and intensify anticholinergic and sedative effects.
Drugs that inhibit hepatic CYP enzymes may alter doxylamine metabolism, affecting plasma levels and toxicity potential.
May cause false negatives in allergy skin testing by masking histamine-mediated skin reactions.
Potentiation of sedative effect can occur with concomitant use of antidepressants, antipsychotics, or anticonvulsants.
Additive hypotensive effects possible with other medications that cause CNS depression or vasodilation.
Interaction with cholinesterase inhibitors may reduce their efficacy due to antagonistic pharmacodynamics.
Combination with agents decreasing renal clearance may require monitoring of doxylamine accumulation.
Synergistic CNS depression with other sleep aids or anti-anxiety medications necessitates careful dosing.
Potential interaction with herbal products such as valerian or kava that have sedative properties.
Interaction risks higher in elderly or debilitated patients requiring close clinical monitoring.
Consult healthcare professionals before adding any over-the-counter cold, allergy, or sleep remedies.

Preparations Of The Drug

Unisom SleepTabs containing 25 mg of doxylamine succinate per oral tablet.
Non-prescription over-the-counter oral tablets formulated for sleep aid and allergy symptom relief.
Combination sleep aid and cold/allergy preparations with doxylamine and other active ingredients (available in some regions).
Unisom Nighttime Sleep Aid variants with similar doxylamine content marketed under alternative brand names.
Extended-release formulations are not commonly available; immediate-release forms are standard.
Multi-symptom cold formulations including doxylamine for relief of allergy and respiratory symptoms in adults.
Available in blister packs or bottles for retail sale, with labeling indicating short-term use.
Product formulations generally free of alcohol, gluten, and common allergens but check packaging to confirm.
Packaging designed to limit pediatric access given potential toxicity in children.
Single ingredient doxylamine tablets intended primarily for short-term treatment of insomnia and allergy symptoms.
Various strengths tailored for specific indications are limited; 25 mg is the most standard dose.
Some regional versions may include additional excipients or inactive ingredients for product stability.
Formulations intended for oral administration only; no parenteral or topical formulations approved.
Inclusion in combination with other nonprescription agents should be used with caution to avoid overdose.
Available under other brand names such as Sleep Aid, Nighttime Sleepaid, Equate Sleep Aid, and Equaline Sleep Aid.